Skip to content
Colorectal Cancer Clinical Trials

Houston, Texas

Colorectal cancer clinical trials in Houston, TX

140 colorectal cancer studies are recruiting participants at sites in Houston as of November 16, 2026, according to ClinicalTrials.gov. Colorectal Cancer Clinical Trials can help you understand your options and connect with a study team.

Call (888) 385-9581
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Houston at a glance

  • 140 studies are recruiting at a site in Houston.
  • By phase: Early Phase 1 (2), Phase 1 (46), Phase 1/2 (38), Phase 2 (20), Phase 2/3 (2), Phase 3 (8), Phase 4 (1), No phase (10), Observational (13). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (95), university, hospital or other (43), government (2).
  • Most recent update to one of these records: November 16, 2026.

Studies recruiting in Houston

Basic details from each study's public record (the 30 most recently updated of 140). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Boehringer Ingelheim
    Study sites
    The Methodist Hospital Research Institute · The University of Texas MD Anderson Cancer Center
    Registry record
    NCT06324357 · updated
  2. A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

    • Phase 1/2
    • Ages 18 to 75
    • All sexes
    Sponsor
    Tyligand Pharmaceuticals (Suzhou) Limited
    Study site
    MD Anderson Cancer Center
    Registry record
    NCT06385925 · updated
  3. A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors

    • Phase 1
    • Ages 18 to 99
    • All sexes
    Sponsor
    Erasca, Inc.
    Study site
    The University of Texas MD Anderson Cancer Center
    Registry record
    NCT06983743 · updated
  4. A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Astellas Pharma Global Development, Inc.
    Study site
    Next Oncology - Houston
    Registry record
    NCT07488676 · updated
  5. A Study to Assess Safety and Efficacy of SOT109 in Patients With Advanced Unresectable or Metastatic Colorectal Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    SOTIO Biotech a.s.
    Study site
    NEXT Houston
    Registry record
    NCT07693751 · updated
  6. Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    M.D. Anderson Cancer Center
    Study site
    M D Anderson Cancer Center
    Registry record
    NCT04739072 · updated
  7. Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    M.D. Anderson Cancer Center
    Study site
    M D Anderson Cancer Center
    Registry record
    NCT05195710 · updated
  8. Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.

    • No phase
    • Ages 18 and older
    • Female participants
    Sponsor
    M.D. Anderson Cancer Center
    Study site
    M D Anderson Cancer Center
    Registry record
    NCT05649072 · updated
  9. A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Vividion Therapeutics, Inc.
    Study site
    MD Anderson Cancer Center
    Registry record
    NCT06004245 · updated
  10. A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pliant Therapeutics, Inc.
    Study sites
    NEXT Houston · University of Texas MD Anderson Cancer Center
    Registry record
    NCT06270706 · updated
  11. Precision-MRD: Prospective Observational Study of Biomarker-directed Systemic Therapy for Colorectal Cancer Patients With Minimal Residual Disease

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    M.D. Anderson Cancer Center
    Study site
    MD Anderson Cancer Center
    Registry record
    NCT06878131 · updated
  12. Shield Post-Approval Study Protocol

    • Observational
    • Ages 45 to 81
    • All sexes
    Sponsor
    Guardant Health, Inc.
    Study site
    Integrity Advanced Therapeutics, PLLC
    Registry record
    NCT06880055 · updated
  13. Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    M.D. Anderson Cancer Center
    Study site
    The University of Texas M. D. Anderson Cancer Center
    Registry record
    NCT06959550 · updated
  14. A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Kestrel Therapeutics, Inc.
    Study site
    The University of Texas MD Anderson Cancer Center
    Registry record
    NCT07458347 · updated
  15. Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    M.D. Anderson Cancer Center
    Study site
    MD Anderson Cancer Center
    Registry record
    NCT07500298 · updated
  16. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Study site
    The University of Texas MD Anderson Cancer Center
    Registry record
    NCT07659795 · updated
  17. Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study sites
    The University of Texas MD Anderson Cancer Center · The University of Texas, MD Anderson Cancer Center - West Houston
    Registry record
    NCT04557449 · updated
  18. Role of Diet on the Microbiome of the Digestive System

    • Observational
    • Ages 45 and older
    • All sexes
    Sponsor
    M.D. Anderson Cancer Center
    Study site
    M D Anderson Cancer Center
    Registry record
    NCT04666727 · updated
  19. A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Study site
    MD Anderson Cancer Center
    Registry record
    NCT07020221 · updated
  20. A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    IDEAYA Biosciences
    Study sites
    MD Anderson · NEXT Texas LLC - Houston
    Registry record
    NCT07503808 · updated
  21. Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UT MD Anderson Cancer Center
    Registry record
    NCT06102902 · updated
  22. A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    M.D. Anderson Cancer Center
    Study site
    MD Anderson Cancer Center
    Registry record
    NCT05411718 · updated
  23. Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Summit Therapeutics
    Registry record
    NCT07228832 · updated
  24. A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study sites
    The University of Texas - M.D. Anderson Cancer Center · The University of Texas, MD Anderson Cancer Center - West Houston
    Registry record
    NCT07318805 · updated
  25. FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Oncolytics Biotech
    Study site
    The University of Texas MD Anderson Cancer Center
    Registry record
    NCT07446322 · updated
  26. Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    NRG Oncology
    Study sites
    Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center · Ben Taub General Hospital · Lyndon Baines Johnson General Hospital
    Registry record
    NCT05174169 · updated
  27. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

    • Observational
    • Ages 40 to 75
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    UT MD Anderson Cancer Center
    Registry record
    NCT05334069 · updated
  28. A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    The University of Texas - MD Anderson Cancer Center
    Registry record
    NCT06400472 · updated
  29. A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Jazz Pharmaceuticals
    Study site
    MD Anderson Cancer Center
    Registry record
    NCT06695845 · updated
  30. A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Bayer
    Study site
    The University of Texas MD Anderson Cancer Center - Texas Medical Center
    Registry record
    NCT06760819 · updated

Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in Houston, TX on ClinicalTrials.gov.

Ask about studies near Houston

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Texas

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Colorectal Cancer Clinical Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 385-9581

or send a short form

How should we reach you?

Call